es prudente no sobrevalorar al IGF-1 como parámetro de seguimiento en la acromegalia.

Por tanto, teniendo en cuenta que la concentración de GH plasmática es el único parámetro con valor pronóstico establecido en la acromegalia, y al menos hasta que aparezcan resultados sobre la utilidad pronóstica de las concentraciones de IGF-1, consideramos necesaria la medición tanto de IGF-1 como de GH en la monitorización de la enfermedad. A la vista de los presentes resultados sería suficiente una determinación aislada de GH, puesto que la medición seriada no reporta mayor información y sí un mayor consumo de recursos humanos y materiales.

BIBLIOGRAFÍA

1. Ho KY, Weissberger AJ. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clin Endocrinol 1994;41:75-83.
2. Ho PJ, Jaffe CA, Friberg RD, Chandler WF, Barkan AL. Persistence of rapid growth hormone (GH) pulsatility after successful removal of GH-producing pituitary tumors. J Clin Endocrinol Metab 1994;78:1403-10.
3. Tsai JS, Zorrilla LL, Jacob KK, Rosenberg S, Marcus DL. Nocturnal monitoring of growth hormone, insulin, C-peptide, and glucose in patients with acromegaly. Am J Med Sci 1996;311:281-5.
4. Hartman ML, Pincus SM, Johnson ML, Matthews DH, Faunt LM, Vance ML, et al. Enhanced basal and disorderly growth hormone secretion distinguish acromegalic from normal pulsatile growth hormone release. J Clin Invest 1994;94:1277-88.
5. Bates AS, Evans AJ, Jones P, Clayton RN. Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion. Clin Endocrinol 1995;42:417-23.
6. Van der Lely AJ, Harris AG, Lamberts SW. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clin Endocrinol 1992;37: 181-5.
7. Russell-Jones DL, Weissberger AJ. The role of growth hormone in the regulation of body composition in the adult. Growth Regul 1996;6:247-52.
8. Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 1979;301: 1138-42.
9. Wass JA, Clemmons DR, Underwood LE, Barrow I, Besser GM, Van Wyk JJ. Changes in circulating somatomedic-C levels in bromocriptine-treated acromegaly. Clin Endocrinol 1982;17:369-77.
10. Giustina A, Barkan A, Casanueva F, Cavagnini F, Frohman L, Ho K, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85:526-9.
11. Parkinson C, Ryder DJ, Trainer PJ. The relationship between serum GH and serum IGF1 in acromegaly is gender-specific. J Clin Endocrinol Metab 2001;86:5240-4.
12. Clemmons DR, Underwood LE. Somatomedin-C/insulin like growth factor I in acromegaly. J Clin Endocrinol Metab 1986; 15:629-53.
13. Hall K, Lundin G, Povoa G. Serum levels of the low molecular weight form of insulin-like growth factor binding protein in healthy subjects and patients with growth hormone deficiency, acromegaly and anorexia nervosa. Acta Endocrinol 1988;118: 321-6.
14. Gama R, Labib M, Teale JD, Marks V. Acromegaly with a misleading insulin-like growth factor 1. Ann Clin Biochem 1989;26:102-3.
15. Rieu M. Evaluation of insulin-like growth factor (somatomedin) levels in acromegaly. Horm Res 1986;24:112-5.
16. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 2002;87:3537-42.
17. Roelfsema F, Frolich M, Van Dulken H. Somatomedin-C levels in treated and untreated patients with acromegaly. Clin Endocrinol 1987;26:137-44.
18. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. QJM 1993;86:293-9.
19. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 1994;41:95-102.

Fe de errores

En el artículo "Hiperglucemia grave con coma hiperosmolar y acidosis láctica inducida por L-asparraginasa y prednisona" publicado en Endocrinol Nutr 2003;50(8):348-50, los autores A. Arranz, V.M. Andía y A. López-Guzmán pertenecen a la unidad de Endocrinología del Hospital de Nuestra Señora de Sonsoles. Ávila. España.